All In Biotech

Drug Trial Radar · NCT05217680

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

Phase III Non-inferiority Clinical Study to Evaluate the Efficacy and Safety of Intravitreous PRO-169 Compared to Ranibizumab for Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 509 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

509

Actual

Start

May 24, 2021

Primary completion

Aug 18, 2025

Study completion Nov 25, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III clinical study to evaluate the efficacy, expressed as improvement in visual acuity in patients suffering diabetic macular edema after one year of treatment with PRO-169, compared to treatment with Lucentis® (ranibizumab).

Conditions

  • Diabetic Macular Edema

Interventions

  • BevacizumabBiological

    Administration of monthly intravitreal bevacizumab (4-12 injections)

  • Lucentis®Biological

    Administration of monthly intravitreal ranibizumab (4-12 injections)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Corrected Visual AcuityTime frame: Day 30±3 (Visit 2), Day 60±3 (Visit 3), Day 90±3 (Visit 4), Day 120±3 (Visit 5), Day 150±3 (Visit 6), Day 180±3 (Visit 7), Day 210±3 (Visit 8), Day 240±3 (Visit 9), Day 270±3 (Visit 10), Day 300±3 (Visit 11), Day 330±3 (Visit 12), Day 360±3 (Final Visit)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SalaUno Salud, S.A.P.I. de C.V.

    Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.